Oral Presentation

The Antibody-Drug Conjugate (ADC) Loncastuximab Tesirine (ADCT 402) Targeting CD19 Shows Strong in vitro Anti-Lymphoma Activity Both As Single Agents and in Combination

Email this document.

Enter your email address below to send this document.

PLACEHOLDER START

[ninja_form id=1]

Important Notice

I am a Healthcare Professional registered to practice in the U.S.
I am a U.S. Patient or Caregiver
in footer
MENU